Dendritic cells (DCs) play a central role in the immune response by presenting antigens to naïve T cells and therefore, triggering the adaptive arm of the immune response. Interferon-producing killer dendritic cell (IKDC) is a multi-tasking cell that shares phenotypic and functional features of both natural killer (NK) cells and DC. Following activation by toll-like receptor (TLR) ligands or tumor cells, IKDC develops cytotoxic properties and subsequently matures into a DC-type of cell able to present antigen to naïve T cells. This "bi-typic" function is associated with innate and adaptive immunologic features, which mark these unique APCs as an attractive direct link between natural and acquired immunity. DCs are promising vectors for the design of effective anti- tumor immunotherapies. They are potent adjuvants because of their immunostimulatory effects on T cells and their coordinated cellular cooperation with all the cellular elements of the immune response. However, tumor generate an immunosuppressive environment with over-expression of the signal transducer and activator of transcription (Stat)-3, leading to production of cytokines such as IL-10 or TGFβ, recruitment of myeloid-derived suppressor cells (MDSC) and tumor -associated macrophages (TAM), or expression of B7-H1, among other mechanisms. This generates inadequately stimulated DCs, which suppress effector responses. Therefore, the new trend in cancer immunotherapy is the combination of DC vaccine or T cell therapy with a chemotherapy causing immunogenic tumor death, with DC activation, enhanced antigen cross-presentation or reduction of the immunosuppressive process.
|Original language||English (US)|
|Title of host publication||Natural Killer Cells|
|Number of pages||13|
|State||Published - Dec 1 2010|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)